drugset / Trial / NCT07114861
The KN510713 Study in Combination With mFOLFIRINOX
Non-randomizedSequentialOpen-labelTreatment
Summary
This study is designed to evaluate the safety and efficacy of KN510713 in combination with mFOLFIRINOX in patients with locally advanced or metastatic pancreatic cancer. The study will be conducted in two parts: Part 1 (Dose-finding) and Part 2 (Dose expansion).
Timeline
- Start
- 2025-12-16
- Primary completion
- 2028-09-22
- Completion
- 2028-10-22
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | KN510 | Unknown | 120 mg | — |
| Subject | KN713 | Unknown | 90 mg | — |
| Subject | KN713 | Unknown | 120 mg | — |